Connection
M Cave to Isoniazid
This is a "connection" page, showing publications M Cave has written about Isoniazid.
|
|
Connection Strength |
|
|
|
|
|
0.114 |
|
|
|
-
Hazb?n MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garc?a-Garc?a L, Le?n CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Le?n A, Alland D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006 Aug; 50(8):2640-9.
Score: 0.069
-
Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1360-6.
Score: 0.015
-
Braden CR, Morlock GP, Woodley CL, Johnson KR, Colombel AC, Cave MD, Yang Z, Valway SE, Onorato IM, Crawford JT. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis. 2001 Sep 15; 33(6):e42-7.
Score: 0.012
-
Hellyer TJ, DesJardin LE, Hehman GL, Cave MD, Eisenach KD. Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. J Clin Microbiol. 1999 Feb; 37(2):290-5.
Score: 0.010
-
Nolan CM, Williams DL, Cave MD, Eisenach KD, el-Hajj H, Hooton TM, Thompson RL, Goldberg SV. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med. 1995 Sep; 152(3):1067-71.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|